Clinical trials: Dialysis Patients
Anaemia, Chronic Kidney Disease (CKD)
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
To describe anaemia correction via haemoglobin measurements taken throughout observation period in ESA naive patients with chronic kidney disease initiated on darbepoetin alfa QM
- Trial name
- ADAPTATION (NCT02185911)
- Where
- 40 sites in Austria, Bulgaria and 6 more
- Volunteers
- 308 people
- Sponsor
- Amgen
Anemia
An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)
This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis.
- Trial name
- NCT02042833
- Where
- 109 sites in France
- Volunteers
- 815 people
- Sponsor
- Hoffmann-La Roche
Secondary Hyperparathyroidism
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT).
- Trial name
- NCT01254565
- Testing
- Etelcalcetide
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- KAI Pharmaceuticals
Anemia
A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
This open label, single arm study will assess the efficacy for long-term maintenance of haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin beta [Mircera] in dialysis patients with chronic…
- Trial name
- NCT01156363
- Testing
- Dialysis, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 3 sites in Taiwan
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
Anemia, Kidney Failure, Chronic
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.
- Trial name
- NCT01999582
- Testing
- Sotatercept
- Where
- 23 sites in Belgium, Germany and 3 more
- Volunteers
- 50 people
- Sponsor
- Celgene
Renal Failure, End Stage Renal Disease
Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
This is a Phase 2, prospective, multicenter, open-label, single-arm study of the Human Acellular Vessel (HAV).
- Conditions
- Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis
- Trial name
- NCT04135417
- Testing
- HAV
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Humacyte, Inc.
Liver Dysfunction, Critical Illness
Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units
Patients with hepatic dysfunction are known to have a high mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate.
- Trial name
- HEPATICUS-2 (NCT01079104)
- Testing
- Hepa Wash, Standard Medical Therapy
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Hepa Wash GmbH
Anemia
Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia
- Trial name
- NCT06720233
- Testing
- SAL-0951 tablets
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Renal Failure, Chronic Kidney Diseases
Influence of Variable Inflow Volume, Dwell Duration and Glucose Concentration on Ultrafiltration Volume in APD Patients
The purpose of the current investigation is to provide proof of concept for a future approach to improve UF prediction accuracy.
- Trial name
- pPD (NCT06443021)
- Testing
- PD cycler
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Renal Anemia of Chronic Kidney Disease
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD)…
- Trial name
- NCT04885647
- Testing
- YPEG-rhEPO
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Anaemia Associated With Chronic Kidney Disease
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III study to determine whether subcutaneous administered efepoetin alfa is as effective and well tolerated as subcutaneous Mircera for…
- Trial name
- NCT04155125
- Testing
- efepoetin alfa, Mircera
- Where
- 55 sites in Australia, Indonesia and 5 more
- Volunteers
- 391 people
- Sponsor
- PT Kalbe Genexine Biologics
Hyperkalaemia
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more…
- Trial name
- GRAZE (NCT04997161)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
The purpose of this study is to determine if PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery to create an arteriovenous fistula is safe and improves the patency of your…
- Trial name
- NCT01305824
- Testing
- PRT-201
- Where
- 23 sites in United States
- Volunteers
- 151 people
- Sponsor
- Proteon Therapeutics
End Stage Renal Disease
Triferic Pediatric Pharmacokinetic Protocol
The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD).
- Trial name
- NCT02595437
- Testing
- Triferic
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Anemia
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease who are not on dialysis and who are receiving subcutaneous darbepoetin alfa…
- Trial name
- NCT00442702
- Testing
- Mircera, Darbepoetin alfa
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted…
- Trial name
- MiD (NCT01779856)
- Testing
- REVEAL Insertable Cardiac Monitor (ICM)
- Where
- 10 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Anemia
A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
This single arm study will assess the efficacy and safety of monthly administration of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera) when administered for the maintenance of hemoglobin levels in participants…
- Trial name
- NCT00642967
- Testing
- Methoxy Polyethylene Glycol-epoetin Beta
- Where
- 69 sites in France
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving Mircera for the treatment of chronic…
- Trial name
- NCT01677767
- Where
- 7 sites in India
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Anemia, Chronic Kidney Disease
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
The primary objective of study is Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2 Part B : To evaluate the proof of concept (POC) of GX-E2
- Trial name
- NCT02044653
- Testing
- GX-E2, NESP, MIRCERA
- Where
- 5 sites in South Korea
- Volunteers
- 257 people
- Sponsor
- Genexine, Inc.
Hyperphosphatemia
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
- Trial name
- NCT01518387
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 11 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Bayer